What is the current valuation of the Human Vaccines Market as of 2024?

The Human Vaccines Market was valued at 666.04 USD Million in 2024. Read More

What is the projected market valuation for the Human Vaccines Market in 2035?

The market is projected to reach a valuation of 1228.11 USD Million by 2035. Read More

What is the expected CAGR for the Human Vaccines Market during the forecast period 2025 - 2035?

The expected CAGR for the Human Vaccines Market during the forecast period 2025 - 2035 is 5.72%. Read More

Which companies are considered key players in the Human Vaccines Market?

Key players in the market include Pfizer, Moderna, Johnson & Johnson, Sanofi, GlaxoSmithKline, Merck & Co., AstraZeneca, Novartis, and Bayer. Read More

How do the valuations of Preventive and Therapeutic Vaccines compare?

Preventive Vaccines are valued between 300.0 and 600.0 USD Million, whereas Therapeutic Vaccines are valued between 150.0 and 300.0 USD Million. Read More

What types of vaccines are included in the Human Vaccines Market?

The market includes Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, and mRNA Vaccines. Read More

What is the valuation range for mRNA Vaccines in the market?

mRNA Vaccines are valued between 216.04 and 328.11 USD Million. Read More

Which routes of administration are prevalent in the Human Vaccines Market?

The prevalent routes of administration include Intramuscular, Subcutaneous, Oral, and Intranasal. Read More

What are the target diseases addressed by the Human Vaccines Market?

The market addresses Viral Infections, Bacterial Infections, Parasitic Infections, and Cancer. Read More

Human Vaccines Market

Q: What are the main segments of the Human Vaccines Market by application?

The main segments by application include Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, and Pediatric Vaccines. Read More

Human Vaccines Market Research Report By Vaccine Type (Inactivated, Live Attenuated, Subunit, Recombinant, Toxoid), By Application (Preventive Vaccines, Therapeutic Vaccines, Travel Vaccines, Influenza Vaccines), By Administration Route (Intramuscular, Subcutaneous, Oral, Intradermal), By Target Diseases (Infectious Diseases, Oncological Diseases, Autoimmune Diseases) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) -Forecast to 2035

Forecast Period

2025 - 2035

CAGR

5.72%

2024 Market Size

$ 666.04 Million

2035 Market Size

$ 1,228.11 Million

Pharmaceutical ● Updated April 2026 Report ID: MRFR/Pharma/1984-HCR | Pages: 200 | Author: Satyendra Maurya, Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Million)
  1. 4.1.1 Preventive Vaccines
  2. 4.1.2 Therapeutic Vaccines
  3. 4.1.3 Travel Vaccines
  4. 4.1.4 Pediatric Vaccines
2. 4.2 Healthcare, BY Type (USD Million)
  1. 4.2.1 Live Attenuated Vaccines
  2. 4.2.2 Inactivated Vaccines
  3. 4.2.3 Subunit Vaccines
  4. 4.2.4 mRNA Vaccines
3. 4.3 Healthcare, BY Route of Administration (USD Million)
  1. 4.3.1 Intramuscular
  2. 4.3.2 Subcutaneous
  3. 4.3.3 Oral
  4. 4.3.4 Intranasal
4. 4.4 Healthcare, BY Target Disease (USD Million)
  1. 4.4.1 Viral Infections
  2. 4.4.2 Bacterial Infections
  3. 4.4.3 Parasitic Infections
  4. 4.4.4 Cancer
5. 4.5 Healthcare, BY End User (USD Million)
  1. 4.5.1 Hospitals
  2. 4.5.2 Clinics
  3. 4.5.3 Pharmacies
  4. 4.5.4 Research Institutions
6. 4.6 Healthcare, BY Region (USD Million)
  1. 4.6.1 North America
    1. 4.6.1.1 US
    2. 4.6.1.2 Canada
  2. 4.6.2 Europe
    1. 4.6.2.1 Germany
    2. 4.6.2.2 UK
    3. 4.6.2.3 France
    4. 4.6.2.4 Russia
    5. 4.6.2.5 Italy
    6. 4.6.2.6 Spain
    7. 4.6.2.7 Rest of Europe
  3. 4.6.3 APAC
    1. 4.6.3.1 China
    2. 4.6.3.2 India
    3. 4.6.3.3 Japan
    4. 4.6.3.4 South Korea
    5. 4.6.3.5 Malaysia
    6. 4.6.3.6 Thailand
    7. 4.6.3.7 Indonesia
    8. 4.6.3.8 Rest of APAC
  4. 4.6.4 South America
    1. 4.6.4.1 Brazil
    2. 4.6.4.2 Mexico
    3. 4.6.4.3 Argentina
    4. 4.6.4.4 Rest of South America
  5. 4.6.5 MEA
    1. 4.6.5.1 GCC Countries
    2. 4.6.5.2 South Africa
    3. 4.6.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Pfizer (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Moderna (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Johnson & Johnson (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Sanofi (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 GlaxoSmithKline (GB)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 AstraZeneca (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Novartis (CH)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Bayer (DE)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 NORTH AMERICA MARKET ANALYSIS
3. 6.3 US MARKET ANALYSIS BY APPLICATION
4. 6.4 US MARKET ANALYSIS BY TYPE
5. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 US MARKET ANALYSIS BY TARGET DISEASE
7. 6.7 US MARKET ANALYSIS BY END USER
8. 6.8 CANADA MARKET ANALYSIS BY APPLICATION
9. 6.9 CANADA MARKET ANALYSIS BY TYPE
10. 6.10 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
11. 6.11 CANADA MARKET ANALYSIS BY TARGET DISEASE
12. 6.12 CANADA MARKET ANALYSIS BY END USER
13. 6.13 EUROPE MARKET ANALYSIS
14. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION
15. 6.15 GERMANY MARKET ANALYSIS BY TYPE
16. 6.16 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
17. 6.17 GERMANY MARKET ANALYSIS BY TARGET DISEASE
18. 6.18 GERMANY MARKET ANALYSIS BY END USER
19. 6.19 UK MARKET ANALYSIS BY APPLICATION
20. 6.20 UK MARKET ANALYSIS BY TYPE
21. 6.21 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
22. 6.22 UK MARKET ANALYSIS BY TARGET DISEASE
23. 6.23 UK MARKET ANALYSIS BY END USER
24. 6.24 FRANCE MARKET ANALYSIS BY APPLICATION
25. 6.25 FRANCE MARKET ANALYSIS BY TYPE
26. 6.26 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
27. 6.27 FRANCE MARKET ANALYSIS BY TARGET DISEASE
28. 6.28 FRANCE MARKET ANALYSIS BY END USER
29. 6.29 RUSSIA MARKET ANALYSIS BY APPLICATION
30. 6.30 RUSSIA MARKET ANALYSIS BY TYPE
31. 6.31 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
32. 6.32 RUSSIA MARKET ANALYSIS BY TARGET DISEASE
33. 6.33 RUSSIA MARKET ANALYSIS BY END USER
34. 6.34 ITALY MARKET ANALYSIS BY APPLICATION
35. 6.35 ITALY MARKET ANALYSIS BY TYPE
36. 6.36 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
37. 6.37 ITALY MARKET ANALYSIS BY TARGET DISEASE
38. 6.38 ITALY MARKET ANALYSIS BY END USER
39. 6.39 SPAIN MARKET ANALYSIS BY APPLICATION
40. 6.40 SPAIN MARKET ANALYSIS BY TYPE
41. 6.41 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
42. 6.42 SPAIN MARKET ANALYSIS BY TARGET DISEASE
43. 6.43 SPAIN MARKET ANALYSIS BY END USER
44. 6.44 REST OF EUROPE MARKET ANALYSIS BY APPLICATION
45. 6.45 REST OF EUROPE MARKET ANALYSIS BY TYPE
46. 6.46 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
47. 6.47 REST OF EUROPE MARKET ANALYSIS BY TARGET DISEASE
48. 6.48 REST OF EUROPE MARKET ANALYSIS BY END USER
49. 6.49 APAC MARKET ANALYSIS
50. 6.50 CHINA MARKET ANALYSIS BY APPLICATION
51. 6.51 CHINA MARKET ANALYSIS BY TYPE
52. 6.52 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
53. 6.53 CHINA MARKET ANALYSIS BY TARGET DISEASE
54. 6.54 CHINA MARKET ANALYSIS BY END USER
55. 6.55 INDIA MARKET ANALYSIS BY APPLICATION
56. 6.56 INDIA MARKET ANALYSIS BY TYPE
57. 6.57 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
58. 6.58 INDIA MARKET ANALYSIS BY TARGET DISEASE
59. 6.59 INDIA MARKET ANALYSIS BY END USER
60. 6.60 JAPAN MARKET ANALYSIS BY APPLICATION
61. 6.61 JAPAN MARKET ANALYSIS BY TYPE
62. 6.62 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
63. 6.63 JAPAN MARKET ANALYSIS BY TARGET DISEASE
64. 6.64 JAPAN MARKET ANALYSIS BY END USER
65. 6.65 SOUTH KOREA MARKET ANALYSIS BY APPLICATION
66. 6.66 SOUTH KOREA MARKET ANALYSIS BY TYPE
67. 6.67 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
68. 6.68 SOUTH KOREA MARKET ANALYSIS BY TARGET DISEASE
69. 6.69 SOUTH KOREA MARKET ANALYSIS BY END USER
70. 6.70 MALAYSIA MARKET ANALYSIS BY APPLICATION
71. 6.71 MALAYSIA MARKET ANALYSIS BY TYPE
72. 6.72 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
73. 6.73 MALAYSIA MARKET ANALYSIS BY TARGET DISEASE
74. 6.74 MALAYSIA MARKET ANALYSIS BY END USER
75. 6.75 THAILAND MARKET ANALYSIS BY APPLICATION
76. 6.76 THAILAND MARKET ANALYSIS BY TYPE
77. 6.77 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
78. 6.78 THAILAND MARKET ANALYSIS BY TARGET DISEASE
79. 6.79 THAILAND MARKET ANALYSIS BY END USER
80. 6.80 INDONESIA MARKET ANALYSIS BY APPLICATION
81. 6.81 INDONESIA MARKET ANALYSIS BY TYPE
82. 6.82 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
83. 6.83 INDONESIA MARKET ANALYSIS BY TARGET DISEASE
84. 6.84 INDONESIA MARKET ANALYSIS BY END USER
85. 6.85 REST OF APAC MARKET ANALYSIS BY APPLICATION
86. 6.86 REST OF APAC MARKET ANALYSIS BY TYPE
87. 6.87 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
88. 6.88 REST OF APAC MARKET ANALYSIS BY TARGET DISEASE
89. 6.89 REST OF APAC MARKET ANALYSIS BY END USER
90. 6.90 SOUTH AMERICA MARKET ANALYSIS
91. 6.91 BRAZIL MARKET ANALYSIS BY APPLICATION
92. 6.92 BRAZIL MARKET ANALYSIS BY TYPE
93. 6.93 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
94. 6.94 BRAZIL MARKET ANALYSIS BY TARGET DISEASE
95. 6.95 BRAZIL MARKET ANALYSIS BY END USER
96. 6.96 MEXICO MARKET ANALYSIS BY APPLICATION
97. 6.97 MEXICO MARKET ANALYSIS BY TYPE
98. 6.98 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
99. 6.99 MEXICO MARKET ANALYSIS BY TARGET DISEASE
100. 6.100 MEXICO MARKET ANALYSIS BY END USER
101. 6.101 ARGENTINA MARKET ANALYSIS BY APPLICATION
102. 6.102 ARGENTINA MARKET ANALYSIS BY TYPE
103. 6.103 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
104. 6.104 ARGENTINA MARKET ANALYSIS BY TARGET DISEASE
105. 6.105 ARGENTINA MARKET ANALYSIS BY END USER
106. 6.106 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
107. 6.107 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE
108. 6.108 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
109. 6.109 REST OF SOUTH AMERICA MARKET ANALYSIS BY TARGET DISEASE
110. 6.110 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
111. 6.111 MEA MARKET ANALYSIS
112. 6.112 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION
113. 6.113 GCC COUNTRIES MARKET ANALYSIS BY TYPE
114. 6.114 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
115. 6.115 GCC COUNTRIES MARKET ANALYSIS BY TARGET DISEASE
116. 6.116 GCC COUNTRIES MARKET ANALYSIS BY END USER
117. 6.117 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION
118. 6.118 SOUTH AFRICA MARKET ANALYSIS BY TYPE
119. 6.119 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
120. 6.120 SOUTH AFRICA MARKET ANALYSIS BY TARGET DISEASE
121. 6.121 SOUTH AFRICA MARKET ANALYSIS BY END USER
122. 6.122 REST OF MEA MARKET ANALYSIS BY APPLICATION
123. 6.123 REST OF MEA MARKET ANALYSIS BY TYPE
124. 6.124 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
125. 6.125 REST OF MEA MARKET ANALYSIS BY TARGET DISEASE
126. 6.126 REST OF MEA MARKET ANALYSIS BY END USER
127. 6.127 KEY BUYING CRITERIA OF HEALTHCARE
128. 6.128 RESEARCH PROCESS OF MRFR
129. 6.129 DRO ANALYSIS OF HEALTHCARE
130. 6.130 DRIVERS IMPACT ANALYSIS: HEALTHCARE
131. 6.131 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
132. 6.132 SUPPLY / VALUE CHAIN: HEALTHCARE
133. 6.133 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
134. 6.134 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Million)
135. 6.135 HEALTHCARE, BY TYPE, 2024 (% SHARE)
136. 6.136 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Million)
137. 6.137 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
138. 6.138 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
139. 6.139 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE)
140. 6.140 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Million)
141. 6.141 HEALTHCARE, BY END USER, 2024 (% SHARE)
142. 6.142 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Million)
143. 6.143 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 North America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.2.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.2.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.2.5 BY END USER, 2025-2035 (USD Million)
2. 7.3 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.3.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.3.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.3.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.3.5 BY END USER, 2025-2035 (USD Million)
3. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
  1. 7.4.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.4.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.4.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.4.5 BY END USER, 2025-2035 (USD Million)
4. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.5.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.5.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.5.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.5.5 BY END USER, 2025-2035 (USD Million)
5. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
  1. 7.6.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.6.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.6.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.6.5 BY END USER, 2025-2035 (USD Million)
6. 7.7 UK MARKET SIZE ESTIMATES; FORECAST
  1. 7.7.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.7.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.7.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.7.5 BY END USER, 2025-2035 (USD Million)
7. 7.8 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.8.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.8.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.8.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.8.5 BY END USER, 2025-2035 (USD Million)
8. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
  1. 7.9.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.9.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.9.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.9.5 BY END USER, 2025-2035 (USD Million)
9. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
  1. 7.10.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.10.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.10.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.10.5 BY END USER, 2025-2035 (USD Million)
10. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
  1. 7.11.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.11.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.11.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.11.5 BY END USER, 2025-2035 (USD Million)
11. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
  1. 7.12.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.12.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.12.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.12.5 BY END USER, 2025-2035 (USD Million)
12. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.13.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.13.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.13.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.13.5 BY END USER, 2025-2035 (USD Million)
13. 7.14 China MARKET SIZE ESTIMATES; FORECAST
  1. 7.14.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.14.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.14.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.14.5 BY END USER, 2025-2035 (USD Million)
14. 7.15 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.15.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.15.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.15.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.15.5 BY END USER, 2025-2035 (USD Million)
15. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
  1. 7.16.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.16.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.16.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.16.5 BY END USER, 2025-2035 (USD Million)
16. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
  1. 7.17.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.17.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.17.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.17.5 BY END USER, 2025-2035 (USD Million)
17. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
  1. 7.18.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.18.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.18.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.18.5 BY END USER, 2025-2035 (USD Million)
18. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
  1. 7.19.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.19.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.19.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.19.5 BY END USER, 2025-2035 (USD Million)
19. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
  1. 7.20.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.20.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.20.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.20.5 BY END USER, 2025-2035 (USD Million)
20. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
  1. 7.21.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.21.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.21.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.21.5 BY END USER, 2025-2035 (USD Million)
21. 7.22 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.22.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.22.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.22.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.22.5 BY END USER, 2025-2035 (USD Million)
22. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
  1. 7.23.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.23.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.23.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.23.5 BY END USER, 2025-2035 (USD Million)
23. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
  1. 7.24.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.24.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.24.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.24.5 BY END USER, 2025-2035 (USD Million)
24. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
  1. 7.25.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.25.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.25.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.25.5 BY END USER, 2025-2035 (USD Million)
25. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.26.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.26.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.26.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.26.5 BY END USER, 2025-2035 (USD Million)
26. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.27.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.27.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.27.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.27.5 BY END USER, 2025-2035 (USD Million)
27. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
  1. 7.28.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.28.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.28.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.28.5 BY END USER, 2025-2035 (USD Million)
28. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
  1. 7.29.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.29.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.29.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.29.5 BY END USER, 2025-2035 (USD Million)
29. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
  1. 7.30.1 BY APPLICATION, 2025-2035 (USD Million)
  2. 7.30.2 BY TYPE, 2025-2035 (USD Million)
  3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  4. 7.30.4 BY TARGET DISEASE, 2025-2035 (USD Million)
  5. 7.30.5 BY END USER, 2025-2035 (USD Million)
30. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
1. 7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Human Vaccines Market Segmentation

Human Vaccines Market By Application (USD Million, 2025-2035)

Preventive Vaccines
Therapeutic Vaccines
Travel Vaccines
Pediatric Vaccines

Human Vaccines Market By Type (USD Million, 2025-2035)

Live Attenuated Vaccines
Inactivated Vaccines
Subunit Vaccines
mRNA Vaccines

Human Vaccines Market By Route of Administration (USD Million, 2025-2035)

Intramuscular
Subcutaneous
Oral
Intranasal

Human Vaccines Market By Target Disease (USD Million, 2025-2035)

Viral Infections
Bacterial Infections
Parasitic Infections
Cancer

Human Vaccines Market By End User (USD Million, 2025-2035)

Hospitals
Clinics
Pharmacies
Research Institutions

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”